Naproxen/Esomeprazole Abdi (Esomeprazole, Naproxen)

Naproxen inhibits cyclooxygenase‑1 and‑2 enzymes, reducing prostaglandin production and thereby decreasing pain, swelling, and fever. Esomeprazole irreversibly blocks the gastric H+/K+‑ATPase pump, suppressing acid secretion and providing a protective effect on the stomach lining, especially when NSAIDs are used.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s condition, severity, and response to therapy. The product is supplied as a prescription‑only oral tablet, and patients should follow the exact instructions provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. Naproxen may pose risks to the fetus, especially in the third trimester, and esomeprazole is generally classified as pregnancy category C. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their doctor before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Naproxen/esomeprazole pairs a long‑acting NSAID with a potent proton‑pump inhibitor, offering both anti‑inflammatory efficacy and robust gastric protection in a single tablet. Compared with ibuprofen‑omeprazole or diclofenac‑lansoprazole combos, naproxen provides a longer half‑life, which may allow once‑ or twice‑daily dosing, while esomeprazole delivers consistent acid suppression across a broad patient population.

The tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight. Do not store in bathrooms or near kitchen appliances. Ensure the packaging remains tightly closed until use to maintain product stability.

Naproxen/esomeprazole is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with food can reduce gastrointestinal discomfort. Swallow the tablet whole; do not split, crush or chew it, as this could affect the release characteristics and increase the risk of side effects.

The most serious risks include gastrointestinal bleeding, ulcer perforation, and cardiovascular events such as myocardial infarction or stroke, particularly with prolonged NSAID use. Severe allergic reactions, including anaphylaxis and Stevens‑Johnson syndrome, can also occur. Patients should be monitored for signs of bleeding, chest pain, or severe skin reactions and seek immediate medical attention if they arise.

Individuals with a known hypersensitivity to naproxen, esomeprazole, other NSAIDs, or PPIs should avoid this medication. It is also contraindicated in patients with active peptic ulcer disease, severe heart failure, or recent gastrointestinal bleeding. Caution is advised for patients with severe renal or hepatic impairment, and it should not be used in combination with other NSAIDs or anticoagulants without medical supervision.